Phase 3 results of the Archway trial show patients with neovascular age-related macular degeneration treated with the Port Delivery System with ranibizumab experienced equivalent vision outcomes compared with patients treated with ranibizumab.
“The Archway trial met its primary endpoint with the PDS demonstrating equivalent efficacy and reduced treatment burden compared with the gold standard of monthly injections of ranibizumab. The PDS surgery/device/drug combination was generally well tolerated and had a favorable benefit-risk profile,” Peter A. Campochiaro, MD, said at the
Uncategorized